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Abstract
Background: The recent development of rapid diagnostic tests (RDTs) for human African trypanosomiasis (HAT)
enables elimination programmes to decentralise serological screening services to frontline health facilities. However,
patients must still undertake multiple onwards referral steps to either be confirmed or discounted as cases. Accurate
surveillance thus relies not only on the performance of diagnostic technologies but also on referral support structures
and patient decisions. This study explored why some RDT-positive suspects failed to complete the diagnostic referral
process in West Nile, Uganda.
Methods: Between August 2013 and June 2015, 85% (295/346) people who screened RDT-positive were examined by
microscopy at least once; 10 cases were detected. We interviewed 20 RDT-positive suspects who had not completed
referral (16 who had not presented for their first microscopy examination, and 4 who had not returned for a second to
dismiss them as cases after receiving discordant [RDT-positive, but microscopy-negative results]). Interviews
were analysed thematically to examine experiences of each step of the referral process.
Results: Poor provider communication about HAT RDT results helped explain non-completion of referrals in
our sample. Most patients were unaware they were tested for HAT until receiving results, and some did not
know they had screened positive. While HAT testing and treatment is free, anticipated costs for transportation
and ancillary health services fees deterred many. Most expected a positive RDT result would lead to HAT treatment.
RDT results that failed to provide a definitive diagnosis without further testing led some to question the expertise of
health workers. For the four individuals who missed their second examination, complying with repeat referral requests
was less attractive when no alternative diagnostic advice or treatment was given.
Conclusions: An RDT-based surveillance strategy that relies on referral through all levels of the health system is
inevitably subject to its limitations. In Uganda, a key structural weakness was poor provider communication about the
possibility of discordant HAT test results, which is the most common outcome for serological RDT suspects in a HAT
elimination programme. Patient misunderstanding of referral rationale risks harming trust in the whole system and
should be addressed in elimination programmes.
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Background
Human African trypanosomiasis (HAT, also known as
sleeping sickness) is a fatal but treatable disease trans-
mitted by tsetse flies. Owing to the weakness of health
systems in areas where HAT occurs, an unspecified
number of HAT cases still go undetected and unreported
[1]. A key reason why HAT is under-detected relates to
the complexity of diagnosis and treatment. The symptoms
of HAT are typically intermittent, progressive and can be
confused with other locally endemic diseases such as
malaria, tuberculosis, or HIV infection which may also
coexist with HAT [2]. Although trial results for new
oral drugs in development suggest treatment regimens
may become simpler and safer in future [3, 4], the need
to manage adverse reactions and the costs associated with
providing treatment1 means that patients suspected to have
HAT based on symptoms are not treated presumptively.
Microscopy-based examinations which confirm infection
by allowing the parasite to be visualized in body fluid are
therefore necessary, but are laborious and not very sensi-
tive. Screening tests that identify trypanosome-specific anti-
bodies or parasite DNA or RNA suggestive of infection
may therefore also be used to complement microscopy in a
variety of sequences, depending on disease prevalence and
a control programme’s access to laboratory resources [6].
Mobile teams, which have been extensively used to
screen at-risk populations in epidemics throughout the
twentieth century [7], typically travelled with all laboratory
equipment needed to confirm a case who would then be
treated in hospital. In non-epidemic scenarios when mo-
bile teams are regarded as too expensive and struggle to
achieve sufficient coverage [8, 9], programmes typically
revert to a passive case detection strategy with diagnosis
restricted to places, usually hospitals, which can similarly
perform all screening and confirmation tests in sequence
[9–12]. In the rural areas where HAT is most endemic,
however, such well-equipped hospitals are rare.
To improve the passive surveillance capabilities of
countries seeking to eliminate HAT, programmes across
Africa have recently devised novel case detection strategies
to take advantage of new diagnostics which are easier to
use and/or to build laboratory capacity to take advantage of
tests previously considered too sophisticated for field set-
tings [10]. Serological rapid diagnostic tests (RDTs) are an
example of a diagnostic which is easy enough to be used in
frontline primary healthcare facilities without electricity,
cold chain or specific laboratory expertise. However, unlike
malaria RDTs for example, HAT RDTs detect circulating
antibodies, and therefore remain “screening”, rather than
“diagnostic” tests in the strict sense. Their imperfect specifi-
city also means that at typical elimination prevalences seen
today they have a very low positive predictive value (PPV)
[13] such that 99 false positives are produced for every true
case [14]. Loop-mediated isothermal amplification (LAMP)
which identifies parasite DNA [15], as well as the trypanoly-
sis test which uses cultures of live trypanosomes to identify
strain-specific antibodies [16] are examples of tests that are
only performed in certain laboratories in Africa and Europe
[17]. These can be used alongside RDTs to generate further
evidence to increase diagnostic suspicion and demand for
confirmatory tests.
By involving more health workers in HAT diagnosis at
multiple health systems levels, this maturation in passive
detection approaches addresses critiques in the HAT lit-
erature which view a move away from active screening
as leaving the door open to disease resurgence based on
health system weaknesses. HAT screening campaigns
have sometimes been considered “vertical interventions
(…) deployed in the absence of local healthcare infrastruc-
ture” [18] with the risk that the “progressive dismantling”
of highly specialised mobile teams who possess the most
expertise in HAT diagnosis could therefore have “grave
consequences at the individual and community level” [14].
With diagnostic technologies now spread across three
(or more) levels of the health system [10], however, this
means that programmes must find innovative ways to
manage a diagnostic algorithm for passive surveillance
which is now routinely split up over geographic spaces.
Either patients and/or samples will have to travel between
health facilities and programmes will have to monitor
these movements.
Previous innovations have focused mainly on transport-
ing samples collected in medical surveys for remote screen-
ing to reduce the time full mobile teams have to spend in
individual villages. This includes preserving blood samples
in a stabilization buffer or as dried blood spots on filter
paper for screening with the card agglutination test for
trypanosomiasis (CATT) or its microCATT and latex
agglutination variants [19, 20]; the indirect immuno-
fluorescent antibody test (IFAT) [21, 22] and the trypa-
nolysis test [13, 23, 24]. Positive results typically
triggered a follow-up visit by a small, specialist mobile
team. Sample collection for remote screening has, how-
ever, rarely been used in a passive surveillance strategy
despite long-term recognition of the potential value of
equipping frontline facilities to collect samples “at any
moment” [21]. Although syndromic referrals have al-
ways been made from concerned health workers at
ill-equipped facilities [25], until a few years ago, there
were also few, if any, examples of programmes which
asked serological suspects detected in a medical survey
or frontline facility to travel to a different health system
level for further testing [26, 27].2 Today there is a
Lee and Palmer Infectious Diseases of Poverty  (2018) 7:84 Page 2 of 16
relative explosion of interest in piloting and studying the
effectiveness of these technologies in new sequences and
strategies [28, 29].
People who screen positive in these new passive
screening strategies are implicitly expected to undertake
a significant role in confirming (or disproving) their own
diagnosis. Moreover, there is substantial work involved
for both programmes and patients to make sense of dis-
cordant results, since patients who screen positive with
RDTs but negative in subsequent tests must be followed
up so they can either be confirmed or discounted as a
case. Even without the extra layers of referral introduced
by passive RDT-based systems, most HAT programmes
typically achieve low levels of follow-up of persistent
serological suspects in whom parasites cannot be identi-
fied but immune responses continue to be detected [17]
or of treated patients to verify cure [8, 30].
In a rural context of material poverty, as in most
HAT-endemic areas, structural and financial barriers
play significant roles in treatment seeking decisions at
each step of the passive surveillance referral pathway,
beginning at the community level [11]. Patient motivation
to keep seeking treatment for undiagnosed symptoms or
to complete referrals may be severely diminished by high
transportation costs, direct health care costs of recurrent
treatment-seeking, competing family and agricultural re-
sponsibilities or restrictive employment systems for taking
leave [25]. Age, gender and ethnicity of the patient [25],
patient perceptions of severity and treatability of symp-
toms [31], and knowledge of treatment requirements
[32, 33] may also influence referral completion. More-
over, unattractive aspects of the culture of care at receiv-
ing facilities produced by long waiting times, dismissive or
harsh treatment by health workers, language barriers and
recurrent drug stock-outs can dissuade patients from
completing referral [34, 35]. Even if patients manage to
reach facilities they have been referred to, there can be
problems with patient processing and lab service unavail-
ability [25] compounded by poor communication about
referral linkages and poorly integrated recording and
monitoring systems [36] that prevent referral consulta-
tions or tests from being carried out.
At each of these health systems levels, relationships of
trust and power between patients and health providers is
a key dynamic to understand programme compliance
[37], with trust built partially on what people see and
hear about technology (including diagnostics [38]) and
institutions [39]. Thus, referral completion involves not
only technical and organisational considerations, but
also expectations and emotions [34]. Many studies of the
referral process conclude that low referral completion
reflects more about the health system than the patient,
since “every non-respected referral is an unsatisfied pa-
tient with an expressed need but with an inadequate
response of the health service” [35, 40] and suggest re-
ferral non-completion be defined in broader terms than
simply the deviant, ‘non-compliant’ behaviour of patients
[41]. For a referral-based intervention to succeed, patients
potentially need trust in both referring and receiving facil-
ities as well as programme supervision structures which
support patients to move between them.
While the risks that referral non-completion poses to
elimination programmes are widely recognised [14, 42], in
depth qualitative studies on HAT referral non-completion
from the perspective of patients themselves are few. In the
West Nile region of Uganda which has recently decentra-
lised its passive surveillance system, we examined patient
experiences and perceptions of HAT, HAT tests and each
of these parts of the health system in relation to HAT test-
ing, to identify systemic challenges to referral completion
by HAT screening suspects.
Methods
Context
Decades of wide-scale active and passive population screen-
ing using the CATT test with standard microscopy tech-
niques as well as vector control reduced the number of
reported Trypanosoma brucei gambiense HAT cases in
Uganda from a peak of 1123 cases in 1997 to only 9 in
2013 [43]. Owing to the costliness of active screening in
such a low prevalence context and the availability of new
diagnostic technologies, the national control programme
has since switched to an enhanced passive surveillance
strategy [10]. Under the donor-funded Intensified Sleeping
Sickness Elimination Programme (ISSEP, now called
Trypa-No!) [29], between August 2013 and February 2014,
the Ministry of Health introduced three new diagnostic
technologies at increasing levels of the public health system
across seven districts in the West Nile region of north west
Uganda (see Fig. 1). All 212 health facilities in areas of West
Nile believed to be at risk of gambiense-type HAT
transmission were supplied with HAT RDTs [10].3 Nine
well-maintained and staffed facilities in the project area
were trained and equipped with fluorescent microscopes to
enhance parasitological visualisation in blood samples.
Three of these facilities were also upgraded to perform
LAMP testing.4 The programme also conducted commu-
nity sensitisation to circulate knowledge of the tests among
the public during the first year of the programme, through
meeting community leaders and radio broadcasts [10].
Health workers were trained in syndromic suspicion of
gambiense HAT, and on the new diagnostic algorithm
(see Fig. 2). In it, only patients with symptoms suggestive
of HAT are offered the RDT. Patients who exhibit symp-
toms also suggestive of malaria are first tested with a
malaria RDT. If a negative result for malaria is recorded,
or a positive result but symptoms persist after one week
of treatment, then a HAT RDT is used. Patients who
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screen positive with the HAT RDT (‘RDT+ suspects’)
are referred to the closest facility where parasitological
investigations can be carried out such as cervical gland
puncture (GP), blood smear staining for use with fluor-
escent microscopy (FM) or capillary tube centrifugation
(CTC) of blood to concentrate parasites in the buffy
coat. If parasites are identified, patients are treated.
Otherwise, a blood spot dried on filter paper is trans-
ferred by motorcycle to a facility where it can be tested
using LAMP. As LAMP is currently an experimental
test, hospitals are required to gain patients’ informed
consent to this. LAMP results are communicated via
mobile text message to the patient. If the LAMP test is
positive, then the suspicion of HAT is strengthened and
the patient must return immediately to have microscopy
repeated. If both parasitology and LAMP tests are nega-
tive, then the patient is requested to return for a quar-
terly follow-up visit. Patients are then tested every three
months with HAT RDTs until they become seronegative,
or are confirmed as cases [10].
Although this programme reported high referral com-
pletion in its first year (see next section), the issue of
suspects ‘defaulting’ on their referrals was described by
programme staff as a significant challenge to their work.
To address this while avoiding introducing unsustainable
administrative and financial practices, the ISSEP granted
programme staff at the district level substantial discretion
about how to integrate monitoring and support of RDT+
suspect referrals into existing systems and activities. Most
frequently this included direct telephone communication
with patients, or communicating through local village
health team members operating near the patient’s home
to counsel patients to present for further testing. When
repeated attempts to convince suspects to attend referral
appointments failed, district supervisors themselves would
arrange to travel to the patient’s home and collect them in
person. In one district with a LAMP centre and high levels
of referral non-completion, lab personnel were permitted
to collect dried blood samples on filter paper for LAMP
testing, inverting the formal diagnostic algorithm under a
pilot approach.
Patient sample selection
Quantitative patterns across the programme were estab-
lished in July 2015 during a scoping investigation to target
further enquiries; detailed quantitative and qualitative data
on referral completion was then collected from four dis-
tricts over a three-week period in November 2015. In this
stage, supervisors provided lists of RDT+ suspects who
had not completed referral (i.e., were considered ‘referral
outstanding’), helped to select a purposive sample, and
assisted in contacting the individuals in our sample.
By the end of June 2015 (20 months into the programme),
12 495 RDTs had been performed across the West Nile
region, yielding 346 RDT+ serological suspects (2.77%
seropositivity prevalence, Table 1).
Of these, 295 (85.3%) had completed at least one con-
firmatory microscopy visit. Among suspects identified
only at peripheral RDT sites (excluding microscopy and
LAMP centres where confirmatory testing of seroposi-
tive suspects can typically be done on the same day), this
proportion was slightly lower at 81.0% (217/268). Ten
HAT cases had been detected from all sites.
Facilities in the eastern districts of Moyo, Adjumani and
Amuru had reported low numbers of RDT+ suspects and
correspondingly low numbers of outstanding referrals
Fig. 1 Map of West Nile region in Uganda showing locations of HAT-endemic districts included in the ISSEP and locations of referring (red) and
receiving (green) health facilities included in the study sample. (SHP file obtained from public repository [58] and GPS coordinates of facilities
included in the ISSEP taken from interactive online map of HAT diagnostic facilities [58])
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(n = 4 for the first referral step from all three districts
in July 2015). Detailed investigations in November therefore
focused on patients referred from facilities in the four
western and central districts in the ISSEP with high
numbers of RDT+ suspects outstanding for microscopy
investigations: Arua, Maracha, Koboko and Yumbe (see
Table 1, Fig. 1). Supervisors from these four districts were
asked to draw-up a list of RDT+ serological suspects out-
standing for any microscopy visit (n = 94 from beginning
of programme to end-October 2015, see Table 2, Fig. 3).
Patients who had never reported for any microscopy
visit were considered alongside those who had previously
reported for microscopy but had not completed quarterly
follow-up(s), as monitoring instruments had not been
standardised by this time in the ISSEP and some district
supervisors could not differentiate between these patient
groups. Any patient reported by supervisors from previous
follow-up attempts to be living over international borders
(Democratic Republic of Congo or South Sudan, n = 10)
Fig. 2 The Trypanosoma brucei gambiense human African trypanosomiasis diagnostic referral algorithm implemented by the ISSEP in Uganda.
Higher level facilities have all diagnostic technology available at lower level facilities. Suspects must undertake key referral steps through the
health system themselves. Adapted from Wamboga et al. 2017:7 [10]. Note: RDT: Rapid diagnostic tests; HAT: Human African trypanosomiasis; GP:
Glandular puncture; FM: Fluorescence microscopy; CTC: Capillary tube centrifugation; LAMP: Loop-mediated isothermal amplification
Table 1 Cumulative (to end-June 2015) RDTs performed, suspects
identified and suspects outstanding for referral, by district
District RDTs
performed
RDT+ suspects
identified (all
facilities)
RDT+ suspects
(peripheral sites
only)
RDT+ suspects
outstanding
for microscopy
Arua 3925 115 90 23
Maracha 1358 61 57 7
Koboko 2574 66 64 14
Yumbe 1847 39 24 3
Moyo 1921 33 17 1
Adjumani 368 19 5 0
Amuru 502 13 11 3
Total 12 495 346 268 51
RDTs Rapid diagnostic tests, RDT+ RDT positive
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was excluded from follow-up by the research team. From
this reduced list of 84 suspects who had not reported for
microscopy testing, 21 people were purposively selected
for recruitment, aiming for a diverse mix of people chosen
according to referring district and across categories of
three key characteristics we hypothesised might influence
referral completion: length of time since first screening
RDT+, distance between the patient’s village and the mi-
croscopy centre they had been referred to, and subjective
characterisations by district supervisors of the level of
difficulty they had previously had counselling or reaching
patients to complete referrals. Out of five suspects charac-
terised as ‘difficult to convince’, four were selected for in-
clusion in the study and three could be located. Therefore,
of 21 patients selected for the sample, 20 could be located;
all of these consented to participate and were recruited
(see Table 2, Fig. 3).
Sixteen out of 20 RDT+ suspects in our sample had
not completed their first referral visit for microscopy/
LAMP testing (at least one month had elapsed since
screening RDT+, Fig. 4). Four had previously completed
one microscopy visit but were outstanding for their
follow-up RDT test (at least three months had elapsed
since confirmatory testing); in these instances, analysis
focused primarily on reasons for non-completion of the
follow-up examinations, and this difference is indicated
Table 2 Demographic profile of all outstanding RDT+ suspects
in four districts and those interviewed
RDT+ suspects outstanding
Total identified, n (%) Interviewed, n (%)
Total 94 20
District
Arua 30 (31.2) 9 (45.0)
Koboko 22 (23.4) 2 (10.0)
Maracha 20 (21.3) 3 (15.0)
Yumbe 22 (23.4) 6 (30.0)
Gender
Male 34 (36.2) 5 (25.0)
Female 60 (63.8) 15 (75.0)
Age (years)
Median (range) 30 (3–79) 40 (8–76)
Time referral outstanding (months)
Median (range) 12.9 (1.2–26.2) 13.6 (3.0–26.3)
Distance to referral facility (km)
Median (range) 13.0 (1–50)* 15.0 (5–48)
*n = 92 as data on the referring facility was missing for 2 patients
Fig. 3 Sample selection process followed for qualitative interviews
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in the text as ‘RDT +MS- suspect’ for ‘microscopy nega-
tive’. All the suspects completed the necessary outstand-
ing tests after interviews; no parasites were identified
and all were dismissed from further evaluation.
Recruitment
Suspects were mobilised for interviews two days prior by
telephone and/or through village health team and local
council representatives who explained the study. It was
clarified that interviews would be conducted with a re-
searcher independent of the programme and that trans-
portation to a microscopy centre would be available on
the interview day if patients wished to complete refer-
rals. A letter of introduction containing information on
the HAT testing referral process, the study, and tele-
phone numbers for the mobiliser and research team was
left with patients. Interviews took place at the micros-
copy centre while patients waited for confirmatory test
results. For suspects under 18 years of age, adult guard-
ians were interviewed in the presence of patients. No pa-
tients presented with psychiatric symptoms or mental
changes that suggested they could not participate in in-
terviews, per supervisors’ assessments. Verbal informed
consent was obtained from patients on initial contact
and written (or witnessed oral) consent was recorded be-
fore the interview.
Interviews
Interviews followed a semi-structured interview guide
which collected information on: suspects’ symptomatic
course of illness and treatment-seeking; knowledge and
awareness of HAT; awareness, understanding and opinions
of HAT RDTs; understandings of RDT results; and experi-
ence of referral at all stages. This guide was pilot tested in
interviews with people who screened positive during a
concurrent mobile team-led screening campaign and
who were later assembled at microscopy centres for
confirmatory testing. It was also further refined during
the study as new themes emerged. Interviews took place
in English or through consecutive translation to local lan-
guages by trained interpreters, as necessary. Discussions
were audio-recorded and full transcripts produced shortly
afterwards, annotated with notes taken during and follow-
ing the interview.
Analysis
Descriptive statistics were produced in an Excel 2016
(Excel for Mac, version 16.10, Microsoft, US) spread-
sheet to compare characteristics of respondents to the
wider sample of people who had not completed referrals;
distances between screening and microscopy sites were
calculated using facility Global Positioning System (GPS)
information available on the programme website [44]. Re-
sponses to each question from the interview topic guide
were consolidated under headings in one document for pri-
mary analysis. Each participant was attributed a unique
identification code with accompanying demographic char-
acteristics to aid interpretation. Recurrent themes for each
topic were then identified, and key quotes that articulated
these themes were selected to summarise each before sec-
ondary analysis across themes. For each theme, we analysed
responses from patients in the two referral completion
groups (RDT+ versus RDT+MS-) separately, but com-
bined them in the final analysis (except where indicated)
Fig. 4 Diagnostic trajectory of patients in our study sample (indicated in bold) and most RDT-positive suspects in an elimination programme. The
16 patients we interviewed who had not presented for parasitology and LAMP testing within 1 month of referral ultimately (after the interview)
tested negative on all subsequent tests. The 4 patients we interviewed who had presented for parasitology and LAMP testing but not for their
quarterly follow-up RDT test ultimately tested negative and were dismissed. *Patients who test positive via parasitological tests are considered
cases, while those who test negative but LAMP-positive are sent back for further parasitological testing
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when they did not substantially differ. Patients’ age and
gender were removed before presentation to preserve ano-
nymity. Quotations presented from study participants were
occasionally edited to correct grammar for readability,
while preserving the meaning and tone of the comments.
Results
Profile of RDT+ suspects interviewed
Of the 20 RDT+ suspects interviewed, more (15/20)
were female, as in the wider 94-person sample of all
outstanding suspects in the four districts (63.8%, see
Table 1). The median age of people interviewed was
40 years old (range 8–76), higher than the median age
(30 years old) of all outstanding suspects. The median
time between first screening RDT+ and our interview
was 13.6 months (range 3.0–26.3, 13.5 for the 16 RDT+
suspects and 16.6 for the four RDT +MS- suspects),
similar to the median outstanding referral time of all
suspects (12.9 months). Participants had been screened
at 13 frontline facilities across the four districts (Fig. 1).
The median distance from respondents’ RDT screening
sites to the facility they were referred to was 15.0 km
(range 5–48 km), slightly further compared to the
whole sample (13.0 km, range 1–50).
Circumstances leading to RDT testing
In all cases in our sample, the decision to use HAT
RDTs was initiated by health workers, rather than on the
request of patients. At the time of interview, most sus-
pects reported having experienced symptoms consistent
with HAT, particularly headaches, fever, or excessive sleep-
ing during the day. HAT-like symptoms were commonly
described as part of a long-term, difficult to diagnose or
treat illness that some patients reported suffering from
for years.
While peoples’ symptoms matched the HAT syndromic
screening profile however, only one person, who had a
family member previously treated for HAT, had ever con-
sidered they might have had the disease before being
tested. Everyone else assumed that they were suffering
from malaria or typhoid or were unsure of what could be
causing their symptoms, so sought diagnosis and treat-
ment from local health facilities and drug shops. Some
additionally considered whether they might be affected by
witchcraft or a common flu, and so took herbal treatment.
The following illness history was illustrative:
It started like malaria. From there I took a step and
went to the clinic. I bought a drug, tablets. I took the
drugs for two to three days, on the third day this thing
threw me down, I was bed ridden […] from there they
[health staff at an ISSEP facility] told me this is not
malaria, what is detected it looks like sleeping sickness.
(RDT+ suspect 19, Maracha)
None of the 20 suspects interviewed reported to have
requested to be tested for HAT themselves, as described
by this patient: “The technician health worker started
just removing blood and testing, and told me they have
found sleeping sickness in my blood. It wasn’t my previ-
ous idea that I am coming to test for sleeping sickness”
(RDT+ suspect 17, Koboko).
Partly, this may relate to the fact that before testing,
awareness of the HAT RDT among respondents was very
low. Only two people (both from Maracha District) had
previous knowledge that the RDT was available at their
local health centre through sensitisation activities. One
respondent in Koboko District knew they were available
in the main referral hospital.
Awareness and feelings about HAT
While patients may not have suspected HAT in them-
selves before being tested for it, the majority of patients
we spoke to appeared to take the disease seriously. This
included an awareness of their own risk from HAT, par-
ticularly after receiving a positive RDT result.
Almost everyone interviewed had personal knowledge
of HAT, having known relatives or people in their village
who had suffered or died from it during outbreaks in
previous years. Other key sources of knowledge included
community sensitisation campaigns associated with med-
ical active screening programmes or tsetse fly control in-
terventions using insecticide treated targets.
At the time of interview, nearly all respondents claimed
to feel there was a risk of HAT in their area. Peoples’ per-
ceptions of risk were discussed in terms of their proximity
to tsetse flies near rivers, ‘the bush’, and dark, densely vege-
tated forest areas. Risk was also interpreted in relation to
the presence of HAT interventions, with comments such
as, “We have that fear because the screening teams came
to our village” (RDT +MS- suspect 1, Arua) and “I have
fear in my hut, I have seen tsetse fly nets being hung up
[nearby]” (RDT+ suspect 19, Maracha).
Given peoples’ lack of awareness of HAT RDTs, their
presence in frontline facilities did not seem to have had
a similar influence on suspects’ perception of HAT risk
prior to testing. Comments about not personally feeling
to be at risk until testing RDT+ such as the following,
however, suggest that the process of screening RDT+
may have heightened some suspects’ perception of per-
sonal susceptibility to HAT: “from the result of my blood
I have that thought that I have sleeping sickness” (RDT+
Suspect 21, Maracha).
Experiences at referring facilities
At referring facilities, patients appeared to have received
little information about the HAT testing process. In all
cases the health worker they visited had tested them for
HAT alongside tests for malaria or typhoid and most
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patients told us they only became aware that they had
been tested for HAT after they received a positive RDT
result. Five people (a quarter in our sample) even left the
facility not understanding they had screened positive for
HAT. Three of these people reported that the first time
they heard they could be infected with HAT was when a
district supervisor, lab supervisor or village health team
member followed-up their outstanding referral, as de-
scribed by the patients quoted below.
That time he [the health worker] did not tell me he
has found sleeping sickness in my blood, but he told
me he has found malaria […] When these technicians
from Yumbe hospital [a microscopy site] went to Kochi
[an RDT site] they gave information to me at home
that they have discovered sleeping sickness in my
blood. I said, ‘why so abrupt like this?’ When I went for
the test they didn’t tell me I had sleeping sickness.
Even my husband had to pick my small patient book
and went to hospital to check, and found that in my
small book it was not indicated that I had sleeping
sickness, but the big book had my name in the list
with the names of people who have sleeping sickness,
that is how I got to know about it. (RDT+ suspect 14,
Yumbe)
I was not told I have sleeping sickness, no one in the
health facility told me that until they wrote
information and sent it through some guy who is doing
business in this trading centre […]. He said, ‘did they
tell you about it when you went for the test?’ I told
him ‘no they did not tell me’. Now they have told me
that I have sleeping sickness. (RDT+ suspect 5, Arua)
Two suspects reported that sensitisation for our inter-
view was the first notification they had received. Such pa-
tients therefore reported not to have known about any
follow-up appointments, nor that they were considered to
have an outstanding referral by the national programme.
Even when results had been given at the time of consult-
ation, however, several people interviewed expressed con-
fusion and even suspicion about why they were being
referred. Only a minority of patients attributed the reason
for referral to limitations of the test, as in the following
excerpt:
“They told me this could possibly be sleeping sickness.
Since their machine’s detective strength is not
adequate I should come to Omugo [a microscopy site]”.
(RDT+MS- suspect 3, Arua).
More often, rather than questioning the reliability of
the RDT, peoples’ confusion about referral rationale was
expressed as distrust in the expertise of referring health
workers who appeared to not be interpreting the results
correctly:
I did not trust them because they told me that I
should come for further testing in Omugo, which
means they failed to interpret the result from the first
test. (RDT+MS- suspect 4, Arua)
It was explained, but he did not explain in a direct
way. He did it in an indirect way, saying that the drug
for sleeping sickness is at Omugo or Arua [another
microscopy site], so you must go there to get the
treatment. (RDT+ suspect 4, Arua)
People who are learned, they automatically use
politics in their speaking. He [health worker] did not
tell me exactly the way you have said, but he showed
me the way so that I can come and discover from this
side (RDT+ suspect 17, Koboko).
When these people told me that I could be having sleeping
sickness I felt they are not being open to me, I was trying
to force them to be open. I thought that if they know that
it is there, they should tell me I have sleeping sickness, so I
was trying to force them. I knew I had sleeping sickness
[because] I would be among other people and I would fall
asleep during the day. That is the symptom I knew meant
I had it. (RDT+MS- suspect 2, Arua)
As evident from the last quote, patients’ own interpre-
tations of their symptoms influenced their trust of test
results and health worker interpretations of them.
While some were sceptical that they could have HAT
because their illness experience was inconsistent with
what they had heard about the disease, others trusted
RDT results because they were “feeling it inside [their]
blood” (RDT+ suspect 10, Yumbe) or in some other way,
saying, for example: “My swollen legs did not change, and
the signs and symptoms I experienced continued, so I be-
lieved I had sleeping sickness” (RDT+ suspect 2, Arua).
Expectations of receiving facilities
Before receiving their results at microscopy centres, pa-
tients reported that they would likely trust the second
round of tests more than the first, associating more reli-
able tests with being conducted in larger hospitals and
requiring larger amounts of blood:
Because I think this is the biggest hospital that can
bring out the truer result than the previous one
(RDT+ suspect 12, Yumbe)
It can differentiate between truth or lies. So if the first
test may say it is true I have sleeping sickness, while
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today it might say it is false, or the first test might say
I don’t have, while here it will say that I have; I will
prove from here (RDT+ suspect 17, Koboko).
Only one patient expressed distrust of the motivations
behind systems in larger hospitals. One RDT +MS- pa-
tient told us she had declined to come for further blood
tests because of family members’ suspicions about blood
stealing, saying:
“I got false information from people that they had
come to steal my blood, so I was not in a position to
come. I spoke to my people at home, but my husband
was not pleased so I would not have come by myself”
(RDT+MS- suspect 2, Arua).
Other characteristics associated with receiving facilities,
besides trust in the tests they offered, thus appeared to in-
fluence most peoples’ decisions not to present, particularly
financial concerns related to referral.
RDT+ suspects frequently cited the cost of transpor-
tation and the difficulty of leaving children at home as
a burden associated with travelling to microscopy cen-
tres. Many people therefore admitted they would likely
not attend a further follow-up appointment if unaided
by the programme. Patients also worried about ex-
penses at the receiving facilities such as ancillary fees
for tests and inpatient care if infection was confirmed.
Though HAT tests are provided free of charge at all
levels of the health system, lab fee structures in Uganda
have inconsistent policies across diseases, so patients re-
ferred for many tests will normally be charged for at
least some of them and some facilities charge a general
lab fee on top of fees for individual tests. This helps ex-
plain one man’s story about deciding not to complete his
HAT referral on a previous trip to the receiving facility.
He said:
When I was taken to Arua, I was to be tested for
sleeping sickness but these people charged me 20,000
shillings. Because I did not pay the 20,000 they did not
test for sleeping sickness, I had to come back home. I
had already got the result that I have sleeping sickness
in Siripi [health centre, an RDT site] but I was referred
for further tests in Arua. They charged 20,000 because
they said they [in Siripi] could not do the second test
from there (RDT+ suspect 4 Arua).
Similarly, very few people were aware that HAT
treatment was free of charge. Patients also anticipated
the costs of food and some in-hospital care costs not
covered by the sleeping sickness programme if admit-
ted for treatment the same day, with one woman
saying:
I need to make sure there is money for transport and
money for feeding. When you are found positive and
you need to be admitted then you also need food and
someone to stay around you. Since I’m just like this by
myself and I have small children, they are not strong
enough to look for things to help me so I could not
come (RDT+ suspect 6, Arua).
One suspect additionally worried about the indirect costs
of treatment even after discharge from hospital, saying:
“When you are vaccinated with that vaccine [referring
to the lumbar puncture used for disease staging] you
cannot work […] I also heard that this treatment
would take long in your body and you would fail to
recover, especially this treatment will fail to treat you
because curses are attached to your life” (RDT+MS-
suspect 3, Arua).
Dealing with discordant results
Receiving discordant (RDT +MS-) results at labs in re-
ceiving facilities which required further diagnostic referral
steps caused some patients to revise their understanding
of which tests could now be trusted to give the ‘true re-
sult’. As one patient described:
I thought that Omugo [Hospital, a microscopy centre]
has to be the one to give the true result […] but they
told me it takes a long process to come up with a
result, so I have to come back and they will send the
result here and the technician will tell me if I am truly
sick (RDT+MS- suspect 1, Arua, referring to the
process of further testing via LAMP)
For others, like at referring facilities, some peoples’
confusion was expressed as distrust in the health staff
that performed their microscopy. This was especially
true for the RDT +MS- suspects whose referrals were
outstanding in our sample. One patient said: “since they
did not cure me, I am not sure of their profession, I’m
not sure of their work […] the health worker, the one
who tested me did not discuss the result with me, in-
stead they discussed it with another health worker”
(RDT +MS- suspect 4, Yumbe).
Realising the financial implications of more travel
associated with conflicting results gave patients the
impression that completing all confirmatory testing would
become a very expensive process. Many patients also
highlighted the unfairness of their compliance with HAT
programme referral rules but not, in turn, being taken of
care of by the same system. One person, for example,
demanded to know from us, “Now that you have brought
us, after testing, will they give us treatment straight away
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or not?” (RDT +MS- suspect 2 Arua). Another suspect
explained: “First I came there and was found positive, and
from here I was told the disease is not there so was told to
come after three months, so I was taken to the other unit
and was on some medication. I took all those drugs, but
still there is no change” (RDT +MS- suspect 1, Arua,
italics authors’). Such suspects, who believed that they did
indeed have HAT, strongly disliked that HAT treatment
could not be given at the moment of testing, as for other
diseases such as malaria. One suspect while awaiting their
microscopy results explained, “because the symptoms I
experience still continue, I expect that today I will be
given some drugs to take home” (RDT+ suspect 2, Arua).
We observed very few (only four) instances of sero-
logical suspects receiving further clinical investigation for
symptoms after microscopy or repeat RDT testing. Typic-
ally, when RDT+ patients arrived at microscopy centres,
clinical staff were briefly called out of the outpatient de-
partment to obtain consent for sending a blood sample for
LAMP testing in the likely event that they tested negative
via microscopy (RDT+ patients) or to record that a sus-
pect had returned for follow-up (RDT +MS- patients).
While clinical staff appeared dedicated to the ethics
consent counselling process, their time was limited and a
full syndromic examination and exploration of alternative
diagnoses did not seem to be part of their usual routine.
Moreover, long outpatient queues of up to 1 h required to
see clinicians after testing negative meant that many pa-
tients preferred to return home and (for RDT+ patients)
wait for LAMP results by phone.
Discussion
The development of RDTs to screen for HAT in recent
years changes the possible configurations of passive sur-
veillance and care in health systems. To understand how
a change towards decentralised testing affects patients,
we interviewed a sample of people who had visited a
frontline facility in Uganda with symptoms suggestive of
HAT, screened positive with RDTs there but failed to
present for a further testing step at higher-level facilities.
Everyone in our sample was eventually determined not
to have the disease. While true cases with more severe
symptoms might be expected to more closely comply
with referral instructions, the majority of patients we
interviewed appeared to take HAT seriously, including
their own risk from it, particularly when receiving a posi-
tive result from a HAT RDT. They also largely trusted the
effectiveness of tests positioned at high level facilities. So
how should we understand their failure to comply with
referral instructions?
A HAT surveillance system which relies on referral
through all levels of the health system will inevitably be
subject to its limitations. We identified issues at both
referring and receiving facilities as well as issues with
navigating between them which made completing refer-
rals challenging for patients.
At referring facilities, there were clear problems re-
lated to communication about the process of testing.
The majority in our sample were not aware they had
been tested for HAT with RDTs until receiving the re-
sult. Power imbalances between health providers and
patients have been suggested to contribute to a culture
of poor communication around HIV testing in Uganda,
whereby many patients are tested without their know-
ledge and miss opportunities to discuss testing rationale
with health staff [45]. In our study, while everyone we
interviewed had been actively seeking care for their
symptoms when tested, most patients never considered
HAT as a possible diagnosis for themselves and most
were unaware of the possibility that they could be screened
for HAT at their local health facility, so HAT-testing in our
sample was entirely health worker-led. This may be a char-
acteristic peculiar to our sample. In a study of 49 HAT re-
ferral decisions narrated by health staff in this programme,
one-fifth were prompted by patients themselves [46]. An-
other study of treatment-seeking trajectories of 877 people
screened passively for HAT (including 38 confirmed cases)
in South Sudan identified lay person-initiated referral as the
most common process associated with screening and suc-
cessful detection [25]. If self-referral for RDT testing is a
common behaviour in this programme, greater dedication
to referral completion in this type of patient might contrib-
ute to the high overall completion rates in the programme.
Relatedly, since communication problems continued
even after patients screened positive for HAT, it raises
the question of whether communicating about referral is
more complicated when testing is initiated by health
workers. A quarter of suspects interviewed, for example,
reported leaving the facility without knowing they could
have HAT –either because referral messages were not
given or not understood. Heavy staff workloads have been
shown to hamper post-test counselling to HIV-positive
patients [47] and contribute to pre-antiretroviral treat-
ment drop out in Uganda [48]. Health workers in the
ISSEP likely had difficulty communicating with patients
about their HAT testing intentions quickly and easily be-
cause of similarly high workloads. Low awareness about
HAT RDTs among the treatment-seeking population also
presumably compounded this.
After leaving facilities, some people in our sample who
had left not knowing they had HAT referrals to complete
were reached by messages from supervisors or village
health teams. While it was clear that some patients in our
sample felt uncomfortable receiving healthcare directions
outside of health facilities this way, it is also likely that
without the flexible methods and personal motivation
of supervisors to ensure programme objectives were
met, the programme would otherwise not have seen
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such high referral completion rates. The ISSEP’s introduc-
tion in 2016 of an information system which automatically
sends reminders to patient’s mobile phones to go for test-
ing will presumably also address some of this communica-
tion gap [10].
Patients also highlighted the direct, indirect and op-
portunity costs associated with travel which provided
practical challenges moving between facilities which are
well-recognised in public health literature [25, 37]. With
patients outstanding for referral living a similar median
distance away from receiving facilities as all people in
the programme, most of whom managed to complete
them (13.0 km in the 94 person sample in our study and
15.0 km in the 20 people we interviewed versus 12.5 km
in the programme overall [10]), however, transportation
issues alone don’t explain non-compliance.
At receiving facilities, some patients anticipated fees
associated with confirmatory testing, particularly if they
were referred for more than just a HAT test. Additionally,
many patients anticipated substantial indirect and oppor-
tunity costs associated with a hospital stay for HAT treat-
ment. Patients talked about delaying referrals because they
needed to raise money for the hospital stay over and above
transport costs, suggesting either an abundance of caution
in preparing for the chance that they would be identified as
cases or that patients conflated a seropositive RDT result
with being a case and needing treatment. The latter explan-
ation is more problematic but has conceptual precedents.
Under the mobile team-led system of HAT screening
which preceded the RDT’s introduction, all patients who
screened seropositive via the CATT test immediately
underwent confirmatory testing and any confirmed
cases identified were offered transportation back to a
hospital for disease staging and treatment. Patients who
could not travel on the same day could report for sta-
ging and treatment in their own time. Compared to the
RDT-based algorithm now in use, the CATT-based al-
gorithm also produced far fewer serological suspects
who required follow-up,5 so very few people were asked
to travel unless they were confirmed HAT cases. But in
an elimination phase, regardless of which screening
tests are used, the proportion of false positives will con-
tinue to increase given the inherent cross reactivity of
antigens used in these tests with other parasites.
Another precedent relates to peoples’ prior experience
with malaria RDTs which prefigured the appropriateness
of RDT technology as the basis for the new HAT case
detection strategy in Uganda as staff were already familiar
with malaria RDTs and implementing their referral algo-
rithms [10]. In most settings where RDTs were introduced
they replaced the need for microscopic examinations in
malaria; today, a positive malaria RDT result normally im-
mediately leads to treatment in the same facility as the test
was done, while a negative result triggers alternative
pathways of care toward further diagnostic procedures
or referral to higher level facilities [38]. If patients are
sent elsewhere for malaria treatment, this is typically
only because the facility is out of stock of drugs –
something that is known to harm peoples’ trust in public
facilities for malaria [49]. Thus, it is reasonable to assume
that few people familiar with either of these precedents
would have expected to be sent home without receiving
treatment after a HAT referral.
Cutting across the system, there were also critical issues
around patients’ interpretations of the contingent nature of
positive HAT RDT results which necessitate referral, and
the related issue of discordant (RDT+MS-) results be-
tween tests. Importantly, discordance is the most common
outcome for serological suspects who complete referral in a
HAT elimination programme given the difference in per-
formance between the different HAT tests currently being
used. None of the suspects in our study were confirmed as
cases after microscopy. Without support to interpret
results, however, several patients felt the truth of their
diagnosis was somehow being concealed from them or
treatment was being denied because health staff were
incompetent or behaving evasively. Patients’ own under-
standing of their symptoms also sometimes influenced this
perception. There is a long history of patients avoiding pro-
grammatic directives in Uganda because they are suspicious
of the motives of health staff [50, 51]. A conceptual discord-
ance for patients thus emerged not only between their trust
in different types of tests but also in their trust between
tests and health workers –or more accurately, the legitim-
acy underlying each. Trust in health workers or institutions
can also be undermined when falsely-positive suspects
do not receive an alternative diagnosis and treatment
for their symptoms when repeatedly presenting to mi-
croscopy centres at great cost to themselves. Studies of
malaria RDTs have shown that health providers work-
ing in under-resourced laboratories are aware of this
risk and compensate by returning falsely positive results
(and unnecessary treatment) to satisfy patient expecta-
tions for an easy to manage diagnosis and to avoid ac-
cusations of incompetence [38].
Community perceptions of HAT control programmes
are not only influenced by historical memories of past
interventions, but shaped by how new methods are intro-
duced. It is unrealistic to expect that community percep-
tions will unreservedly accommodate new interventions
without thorough information dissemination which in-
cludes two-way communication between communities
and programmes [52]. Studies of HIV diagnosis have
shown that the likelihood of patients accepting testing in-
creases with thorough explanation of the testing pro-
cesses, testing venue and understanding what needs to be
done after receiving test results [53]. While all technical
aspects of HAT tests may not need to be communicated
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to patients, false positive or discordant results should be
acknowledged as a normal and expected outcome so as
not to harm health workers’ reputations. Health personnel
must clearly explain to suspects what a positive result
from a HAT RDT really means while stressing the need
for confirmatory testing: that it is an indicator of possible
exposure to HAT and that RDT positivity alone does not
confirm one as a HAT case. Moreover, beyond advertising
the availability of HAT RDTs, HAT programmes should
clarify how the HAT referral system differs from diagnos-
tic systems for other diseases to avoid unmet expectations
stemming from similar language but different diagnostic
meanings shared across the wider health ecosystem [54].
The splitting of passive surveillance diagnostic algo-
rithms across multiple levels of the health system un-
doubtedly adds layers of potential complications to patient
management. Not only are more cadres of health staff now
involved in making sense of discordant results, technical
differences between strategies relying on the RDT com-
pared to the CATT may even create more discordant sero-
logical suspects for the system to deal with as discussed
above. As more RDTs come on to the market, trials are un-
derway to test strategies which use diagnostics in different
combinations, including the use of different RDTs in tan-
dem to improve case detection performance and the use of
sample collection for remote screening at lower health sys-
tem levels to reduce patient travel [28].
HAT elimination surveillance programmes are under-
standably interested in optimising sensitivity since any
missed case can be a potential source of infection from
which epidemics can start to build. On the other hand,
this study has drawn attention to the human cost of
imperfect test specificities in a context of low disease
prevalence. Moreover, that so few patients in our sam-
ple left microscopy facilities with an alternative diagno-
sis or treatment for their ongoing symptoms raises an
important discrepancy between meeting the objectives
of an elimination programme and meeting individual
patients’ needs. Failure to address the latter may have
detrimental effects on referral adherence in the health-
care system as a whole.
Because of our study design we cannot say what drives
referral completion success in this programme which
achieves a remarkably high proportion of completed
referrals (85%). By studying the experiences of referral
completion failure however, we show how, in many
ways, access to HAT testing remains fragmented and
logistically challenging for patients, despite the higher
coverage of screening tests across the system. Additionally,
it is unlikely that the health systems issues we have identi-
fied solely affect people who did not complete referrals and
may be especially important for HAT programmes operat-
ing in places with weaker health systems to understand.
Completion proportions may furthermore diminish for
patient groups at each stage of quarterly follow-up referral
and should be monitored as programmes mature.
Conclusions
While the literature on the role of diagnostics in HAT
elimination largely focusses on coverage and identifying
remaining cases in the population, our study brings to
light the mundane work involved in managing the large
numbers of non-cases produced by an imperfect surveil-
lance system. Furthermore, rather than focussing only
on patients’ health-seeking behaviours in the diagnostic
process [55], we turn our attention to the practicalities
of the entire diagnostic ecosystem [54] and the structural
processes involved in reaching a confirmed HAT diagno-
sis. By focussing on how HAT RDTs fit into the wider
health system, we have also shown some of the ways that
introducing a new RDT can destabilise and disrupt an
established diagnostic ecosystem by creating additional
layers of bureaucracy, further tests, travel, and work for
patients and health workers.
By decentralising passive surveillance across different
levels of the health care system, HAT elimination pro-
grammes across Africa have undergone an unprecedented
transformation. The new strategy enables access to sero-
logical screening in frontline rural health facilities but lim-
itations of the screening test requires patients to then
undertake onwards referral steps by their own means until
they can either be confirmed or discounted as cases. Pa-
tients additionally must manage the uncertainty of ancil-
lary health service charges associated with lab testing and
hospitalisation at higher facilities. As with many other dis-
eases, diagnosing HAT does not end with the initial test
result, but continues throughout treatment pathways with
follow-up tests and continual monitoring [54]. Reaching
diagnostic consensus is thus the combined result of pa-
tient priorities, past precedents, interactions with health-
care providers, and the location and social proximity of
services. A HAT surveillance strategy which relies on re-
ferral through all levels of the health system will inevitably
be subject to the limitations of this system in all of these
domains.
In Uganda, a key health system limitation which helps
explain referral non-completion appears to be weak
communication about HAT testing between health pro-
viders and patients. Poor communication meant that
some patients did not know they had been tested for
HAT when leaving the facility, while others, who did
not understand the need for referrals, blamed health
staff at both referring and receiving facilities for interpret-
ing tests incorrectly. Such misunderstandings are likely
shaped by existing patient knowledge of malaria and prior
HAT diagnostic processes which typically lead to immedi-
ate treatment. Instead, for patients who test positive by
HAT RDTs, the typical outcome is repeated programmatic
Lee and Palmer Infectious Diseases of Poverty  (2018) 7:84 Page 13 of 16
requests to follow-up discordant results that may fail to
result in access to treatment --which is an understandably
unsatisfying experience for patients. It also produces po-
tentially iatrogenic effects on the health system by eroding
important aspects of trust in both diagnostic technologies
and referral structures. Medical historians have shown
that elimination success depends on strong health systems
[56, 57] but the elimination-health systems relationship
can also work the other way around, whereby inappropri-
ate elimination strategies can potentially harm health
systems [56]. While Uganda has achieved a high HAT
referral completion proportion in the first years under
this strategy, effectively addressing health provider com-
munication about the meaning of HAT test results here
[35, 42], and elsewhere, could avoid future mistrust of
HAT referrals and providers as programmes mature.
Endnotes
1All HAT medicines are currently donated by the
pharmaceutical companies who manufacture them, how-
ever, available treatments are complex to administer re-
quiring in-patient admission with additional costs to the
health system [5]
2An exception in some programmes related to a small
group of patients in whom follow-up lab teams could
not find parasites but seropositive reactions were main-
tained after their blood was re-tested with the CATT
test at serial dilutions to rule out non-specific interfer-
ence. Such patients required ‘active follow-up’ which
could include asking them to present to a referral centre
or to a mobile screening team at a later date, but was
considered costly and not always done [8].
3In 2014 the number of facilities receiving RDTs was
reduced to 125 based on the distribution of identified
cases but increased to 149 in 2015 to include more
private clinics and facilities close to refugee camps and
the South Sudanese border.
4LAMP is more sensitive than microscopy and more
specific than RDTs but needs to be performed by techni-
cians with a very high level of training in well-equipped
facilities. Because these sophisticated molecular diagnos-
tics are yet to be ‘field applicable’ in the routine diagnosis
of sleeping sickness at the primary health-care level, the
direct benefit to patients remains limited [59].
5While the CATT test is more cumbersome to use
than an RDT, a key advantage of the CATT test format
is the ability for lab staff to retest blood at serial dilutions
which enables a substantial proportion of patients seroposi-
tive on whole blood to be ruled out for further follow-up.
Depending on the diagnostic algorithm followed in a
programme, those who lose positivity at a ¼ dilution might
be ruled out immediately as a non-case whereas those who
maintain seropositivity at very low dilutions (1/16) might
be managed as if they were cases. This reduces the pool of
patients needing long-term follow-up to only those per-
sistently seropositive at mid-level dilutions (such as 1/
8) [13, 8, 60, 61]. The relative performance of different
RDTs compared to CATT on whole blood or dilutions
in a passive screening setting is a matter of ongoing de-
bate [62, 63].
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